论文部分内容阅读
为观察东菱克栓酶治疗亚急性期脑梗死的疗效及不良反应,对发病后3～10天就诊而未经治疗的亚急性期脑梗死患者56例给予东菱克栓酶治疗(观察组),并与同期56例常规治疗患者(对照组)进行对比。结果:观察组基本痊愈率(39.29％)、显效率(64.29％)和总有效率(85.71％)均明显高于对照组,均有显著性差异(X~2=4.223、5.169、5.009,均P<0.05):其血流动力学指标明显改善,凝血功能指标无明显变化,且无明显不良反应。提示东菱克栓酶对亚急性期脑梗死的治疗是安全有效的。
In order to observe the curative effect and adverse reactions of rhizoma cinctatase in the treatment of subacute cerebral infarction, 56 patients with subacute cerebral infarction who were treated from 3 to 10 days after the onset of treatment were treated with tamoxifen (observation group ), And compared with 56 routine treatment patients (control group) in the same period. Results: The basic recovery rate (39.29%), markedly effective rate (64.29%) and total effective rate (85.71%) in the observation group were significantly higher than those in the control group (X ~ 2 = 4.223,5.169,5.009, P <0.05): The hemodynamic parameters were significantly improved, no significant changes in coagulation parameters, and no significant adverse reactions. Tip bolt Ling bolt subacute cerebral infarction treatment is safe and effective.